Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI116010

Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha.

S Isonishi, A P Jekunen, D K Hom, A Eastman, P S Edelstein, F B Thiebaut, R D Christen, and S B Howell

Department of Gynecologic Oncology, Jikei University School of Medicine, Tokyo, Japan.

Find articles by Isonishi, S. in: JCI | PubMed | Google Scholar

Department of Gynecologic Oncology, Jikei University School of Medicine, Tokyo, Japan.

Find articles by Jekunen, A. in: JCI | PubMed | Google Scholar

Department of Gynecologic Oncology, Jikei University School of Medicine, Tokyo, Japan.

Find articles by Hom, D. in: JCI | PubMed | Google Scholar

Department of Gynecologic Oncology, Jikei University School of Medicine, Tokyo, Japan.

Find articles by Eastman, A. in: JCI | PubMed | Google Scholar

Department of Gynecologic Oncology, Jikei University School of Medicine, Tokyo, Japan.

Find articles by Edelstein, P. in: JCI | PubMed | Google Scholar

Department of Gynecologic Oncology, Jikei University School of Medicine, Tokyo, Japan.

Find articles by Thiebaut, F. in: JCI | PubMed | Google Scholar

Department of Gynecologic Oncology, Jikei University School of Medicine, Tokyo, Japan.

Find articles by Christen, R. in: JCI | PubMed | Google Scholar

Department of Gynecologic Oncology, Jikei University School of Medicine, Tokyo, Japan.

Find articles by Howell, S. in: JCI | PubMed | Google Scholar

Published October 1, 1992 - More info

Published in Volume 90, Issue 4 on October 1, 1992
J Clin Invest. 1992;90(4):1436–1442. https://doi.org/10.1172/JCI116010.
© 1992 The American Society for Clinical Investigation
Published October 1, 1992 - Version history
View PDF
Abstract

A twofold change in the cisplatin (DDP) sensitivity of 2008 human ovarian carcinoma cells is sufficient to reduce tumor response in vivo. The DDP sensitivity of these cells can be enhanced by activation of the epidermal growth factor and protein kinase C signal transduction pathways. We report here that two endogenous growth factors, bombesin and tumor necrosis factor alpha (TNF alpha), enhanced DDP sensitivity by factors of 1.7 +/- 0.1 (SD)-fold and 1.8 +/- 0.1 (SD)-fold, respectively. Both agents also produced sensitization in an 11-fold DDP-resistant 2008 subline. Neither bombesin nor TNF alpha changed the accumulation of DDP, glutathione content, or glutathione-S-transferase activity in 2008 cells. However, a 2-h exposure to both bombesin and TNF alpha was sufficient to increase 2008 cloning efficiency by up to 2.6 +/- 0.1 (SD)-fold and 2.2 +/- 0.1 (SD)-fold, and it increased average colony size by 1.35 +/- 0.1 (SD)-fold and 1.55 +/- 0.1 (SD)-fold, respectively. Bombesin increased intracellular free calcium, and this was blocked by the bombesin receptor-specific antagonist SC196, demonstrating that 2008 cells have functional bombesin receptors. These results indicate that bombesin and TNF alpha can enhance sensitivity to DDP in both DDP sensitive and resistant variants of a human ovarian carcinoma and that both agents serve as growth factors for this tumor.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1436
page 1436
icon of scanned page 1437
page 1437
icon of scanned page 1438
page 1438
icon of scanned page 1439
page 1439
icon of scanned page 1440
page 1440
icon of scanned page 1441
page 1441
icon of scanned page 1442
page 1442
Version history
  • Version 1 (October 1, 1992): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts